Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
NCT02161419 · Bayer · PHASE2 · terminated · last registry update 2018-06-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Bayer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-02-06Also stopped (terminated): Tiziana Life Sciences LTD, Milciclib Maleate (NCT01301391)
- 2019-02-06Also stopped (terminated): Tiziana Life Sciences LTD, Milciclib Maleate (NCT01011439)
- 2018-10-16Results posted on the registry: Tiziana Life Sciences LTD, Milciclib Maleate (NCT01011439)
- 2018-10-04Results posted on the registry: Tiziana Life Sciences LTD, Milciclib Maleate (NCT01301391)
- 2018-03-15Results posted on the registry: National Cancer Institute (NCI), Dinaciclib + Ofatumumab (NCT01515176)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision